CRISPR Therapeutics (NASDAQ:CRSP) said Monday that Vertex Pharmaceuticals (VRTX) subsidiary ViaCyte has elected to opt-out of their development partnership for gene-edited stem cell therapies for the ...

Researchers have used CRISPR to switch back on a gene that vanished from the human lineage roughly 20 million years ago, ...

Analysts project the U.S. diabetes market will surge past $75 billion by 2031, driven by advanced cell therapies and continuous glucose monitoring systems transforming patient care [3]. Regenerative ...

While most of the attention on CRISPR Therapeutics centers on the company’s Vertex-partnered cell therapy and looming FDA advisory committee meeting, Alex Harding, M.D., is cooking up the biotech's ...

Scientists have successfully transplanted gene-edited insulin-producing cells into a man with type 1 diabetes—allowing him to ...

Vertex Pharmaceuticals plans to sell a gene-editing treatment for sickle-cell disease. A patent on CRISPR could stand in the way. That’s a real nice CRISPR cure you have there. It would be a pity if ...

Imagine if you could fix a spelling mistake in a long document with just one click. Now, imagine doing the same with the genetic code of a plant or even a human cell. That’s ...

In July, we reported that lecanemab (Leqembi) won full FDA approval to treat Alzheimer's disease. In this article, we look beyond anti-amyloid agents like lecanemab to see what other targets are being ...

These companies could innovate their way to success.